A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients

Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(2):171-80. doi: 10.1016/0278-5846(90)90099-3.

Abstract

1. Nine severe rapid cycling manic-depressive patients were treated with a magnesium preparation, Magnesiocard 40 mEq/day in an open label study for a period up to 32 weeks. 2. Magnesiocard was found to have clinical results at least equivalent to those of lithium in about 50% of these patients. These results were obtained in an exploratory study and should be interpreted with caution. 3. The possibility that Magnesiocard could replace or improve the efficacy of lithium as a preventive treatment of manic-depressive illness merits further clinical investigation.

MeSH terms

  • Aspartic Acid / adverse effects
  • Aspartic Acid / therapeutic use*
  • Calcium / blood
  • Humans
  • Magnesium / adverse effects
  • Magnesium / therapeutic use*
  • Mood Disorders / drug therapy*
  • Mood Disorders / physiopathology
  • Mood Disorders / psychology
  • Potassium / blood
  • Research Design
  • Sodium / blood

Substances

  • Aspartic Acid
  • Sodium
  • Magnesium
  • Potassium
  • Calcium